.gif)
Clore Laboratory: News
Diabetes, Obesity and Metabolic Research
4 June 2005 – Jon Arch presents results demonstrating anti-obesity effect of CLA to ECO 2005 meeting
Jon Arch, Deputy Director of Metabolic Research, Clore Laboratory, University of Buckingham, UK, gave an oral paper on the anti-obesity effect of conjugated linoleic acid (CLA) at the 14th European Congress on Obesity (ECO), held in Athens, Greece, 1–4 June 2005.
Jon described studies on CLA in genetically obese (ob/ob) mice, conducted in association with Unilever, UK, and Lipid Nutrition, Loders Croklaan, The Netherlands. CLA is present in dairy products and beef fat. Supplements are used to treat obesity in humans, but some, though far from all, studies have suggested that they might exacerbate insulin resistance.The Clore Laboratory studies confirmed the anti-obesity effect of CLA (due to the trans-10, cis-12 isomer) and showed that exacerbation of impaired glucose tolerance was only temporary. However, glucose tolerance and insulin sensitivity were improved after 10 weeks. There is a 12 month study in humans that is consistent with this finding. In reporter gene assays, trans-10, cis-12 CLA activated both PPARα and PPARγ, and this may have contributed to its insulin sensitising effect.
The abstract of the presentation is published in:
Arch JRS, Wargent E, Sennitt MV, Stocker C, Mayes AE, Brown L, O’Dowd J, Wang S, Einerhand AWC, Mohede I, Cawthorne MA. Prolonged treatment of genetically obese mice with conjugated linoleic acid (CLA) improves glucose tolerance and lowers plasma insulin concentration: possible involvement of PPAR activation. Obesity Reviews 2005 6(Suppl 1): 43, Abs T2:O103